FindTrial
Sign In

This study is a prospective, interventional, multicenter, and single-group study to find out the changes in biomarkers related to diabetic nephropathy through additional blood collection and collection tests before and after Finerenone administration among patients diagnosed with type 2 diabetes (T2D)-related chronic kidney disease (CKD)

A Study on Biomarker Changes in the Use of Finerenone in Patients with Diabetes Kidney Disease : A Sub-Study of Fine Real Studies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0011197
Enrollment
100
Registered
2025-11-24
Start date
2025-01-23
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Korea University Ansan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - chronic kidney disease (CKD) related to doctors evaluation (T2D) related to doctors evaluation - Other standard requirements (ARB, ACE information) and illness

Exclusion criteria

Exclusion criteria: If there are one of the following criteria below - eGFR 5.0 mmol/L - patients with this weaknesses of this drug - a patient who has a disease - Loxic acid (galactress) such as Galoxic decomposition (galactress) or glucose (Lappic acid) or glucose (Lappic acid) or glucose (Lapplication) - Patient 3A4 inhibitors who take a strong CYPE and disease drugs

Design outcomes

Primary

MeasureTime frame
Biomarkers Before and After Finerenone—

Countries

Korea, Republic of

Contacts

Public ContactSeungA Park

Korea University Ansan Hospital

redanne@hotmail.com+82-31-8099-3167

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026